Back to top
more

Minerva Neurosciences (NERV)

(Delayed Data from NSDQ)

$2.50 USD

2.50
3,369

+0.06 (2.56%)

Updated Apr 23, 2024 11:59 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NERV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Minerva Neurosciences, Inc [NERV]

Reports for Purchase

Showing records 1 - 20 ( 42 total )

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 1

02/27/2024

Daily Note

Pages: 3

CRL As Expected; FDA Asks For Additional Study; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 2

02/23/2024

Company Report

Pages: 4

CRL Still Most Likely Outcome, In Our View; Phase 1 Trial Offers Hint at Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 3

11/10/2023

Company Report

Pages: 4

No Major Updates as PDUFA Approaches; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 4

08/02/2023

Company Report

Pages: 4

Boehringer Ingelheim Provides Backstop For Roluperidone; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 5

05/16/2023

Company Report

Pages: 6

Lack of AdCom Reduces Chances of Approval; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 6

05/02/2023

Company Report

Pages: 3

Minerva Prevails in Dispute Resolution as FDA Accepts NDA for Roluperidone, Though Many Steps Remain; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 7

03/09/2023

Company Report

Pages: 4

Fewer Options for Roluperidone to Win Approval; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 8

11/10/2022

Company Report

Pages: 5

We Like Roluperidone But Another Study Looks Necessary; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 9

10/18/2022

Company Report

Pages: 4

Another Trial Seems Inevitable as FDA Issues RTF; PT Down to $8, Maintain Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 10

08/23/2022

Company Report

Pages: 5

Roluperidone NDA Submitted as Waiting Game Begins; PT Adjusted Down to $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 11

04/08/2022

Daily Note

Pages: 4

FDA Shows Some Flexibility, But It''s Unclear If That''s Enough for Roluperidone Right Now

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 12

03/04/2022

Company Report

Pages: 5

Preparing for 1H21 Roluperidone Filing; Reiterate Buy; Price Target Lowered to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 13

11/09/2021

Company Report

Pages: 5

FDA Meeting Type Change-up: Detour or Potential Stop Sign for Roluperidone Filing? Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 14

10/01/2021

Daily Note

Pages: 4

Roluperidone Shows Bioequivalence Between Formulations and Pre-NDA Meeting Request Planned; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NERV

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 16

08/03/2021

Company Report

Pages: 5

Bioequivalence Study Completes Enrollment as Pre-NDA Activities Continue; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 17

05/13/2021

Company Report

Pages: 5

Positive OLE Data Bolster Confidence in Roluperidone’s Success; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 18

05/12/2021

Daily Note

Pages: 3

Roluperidone Phase 3 OLE Shows Continuous Improvement; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 19

03/09/2021

Company Report

Pages: 5

Gathering Additional Data to Build Case for Roluperidone; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Minerva Neurosciences, Inc

Industry: Medical - Drugs

Record: 20

01/27/2021

Industry Report

Pages: 15

2021 Roadmap of Key Events Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party